Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq to Delist BG Medicine’s Stock

NEW YORK (GenomeWeb) – BG Medicine said today that its common stock will be delisted from Nasdaq effective at the opening of the Dec. 4, 2015 trading session.

The company was unable to maintain compliance with listing requirements for the exchange.

BG was notified on March 10, 2015 that its stock no longer qualified for listing on the exchange because it did not have a minimum bid price of at least $1 per share, and the company’s stockholder’s equity was not at least $2.5 million.

BG was allowed to continue listing on the exchange as it worked towards regaining compliance, though it was unable to do so. On Sept. 14, 2015, Nasdaq issued a final delisting determination, notifying BG that trading of its stock would be suspended on Sept.16, 2015.

BG did not request a review of this decision, and the decision became final on Oct. 29, 2015.

The company’s stock is now listed on the OTC market.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.